Fusion Pharmaceuticals, a Phase 1 biotech developing radiopharmaceuticals for solid tumors, raised $213 million by offering 12.5 million shares at $17, above the range of $14 to $16. The company originally filed to offer 8.4 million shares at the same range before increasing the share offering to 12.5 million earlier in the week. At pricing, the company commands a fully diluted market cap of $774 million (+25% vs. original terms).
Fusion Pharmaceuticals plans to list on the Nasdaq under the symbol FUSN. Morgan Stanley, Jefferies, and Cowen acted as lead managers on the deal.
